Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax (2017 - 2026)

Kiniksa Pharmaceuticals International's Long-Term Deferred Tax history runs 9 years deep, the most recent figure standing at $193.6 million for Q1 2026.

• Quarterly Long-Term Deferred Tax fell 6.98% year-over-year to $193.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.6 million (down 6.98% YoY) and the FY2025 annual result came in at $198.1 million, down 6.16% from the prior year.
• Long-Term Deferred Tax was $193.6 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $198.1 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $219.3 million in Q4 2023 and bottomed at $184.4 million in Q1 2023.
• A 5-year average of $201.2 million and a median of $203.9 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax advanced 18.22% — and 2026, when it fell 6.98%.
• Kiniksa Pharmaceuticals International's Long-Term Deferred Tax stood at $185.5 million in 2022, then increased by 18.22% to $219.3 million in 2023, then retreated by 3.71% to $211.2 million in 2024, then dropped by 6.16% to $198.1 million in 2025, then decreased by 2.28% to $193.6 million in 2026.
• Business Quant data shows KNSA's Long-Term Deferred Tax at $193.6 million in Q1 2026, $198.1 million in Q4 2025, and $201.3 million in Q3 2025.